S

Sanofi

Global pharma company; vaccines and R&D

Field Medical Associate Director Oncology

Full-TimeDeadline 10/30/26
CA$158.2k - CA$208.2k/yr
Expert
Master's, MBA, PharmD, PhD, MD
Toronto, ON, Canada
RemoteTravel is required up to 75% of the time, primarily within Canada, with some travel elsewhere in North America.
Biology & Biotech

About the job

Requirements
  • A degree from an accredited university (MSc, PhD, PharmD, or MD) is required.
  • A specialization in hematological diseases is preferred.
  • A post-bachelor’s degree from an accredited university, such as an MBA or equivalent, is valuable but not required.
  • At least five years of total experience is required, including at least three years of oncology experience.
  • Prior experience as an MSL or in another field or head-office medical role is required.
  • People management experience is required, preferably in a field medical role.
  • The role requires strategic thinking to anticipate trends, set long-term priorities, and align medical affairs activities with organizational and therapeutic-area goals.
  • The role requires people leadership and coaching to develop and empower team members through mentorship and feedback.
  • The role requires stakeholder engagement with internal and external stakeholders, including KOLs, payers, and regulators.
  • The role requires cross-functional collaboration across departments such as commercial, regulatory, and clinical.
  • The role requires compliance with ethical, regulatory, and internal policies.
  • Written and spoken English is required.
  • Office 365, Zoom, MyTeams, Concur, and Power BI knowledge is required.
  • Travel up to 75% of the time is required, primarily domestic with some travel within North America.
  • Employees with a corporate vehicle must drive safely and comply with applicable laws, regulations, and company directives.
  • Managers on the field must support the Road Safety Program and ensure compliance by drivers under their supervision.
Responsibilities
  • Develop the strategy and tactical plan for scientific-community engagement and oversee effective operation of the oncology MSL organization and substantive scientific exchange.
  • Coordinate with internal stakeholders to develop strategic plans for engaging external key opinion leaders.
  • Guide capability initiatives, including competency-gap analysis, content and curriculum design, training, and monitoring data systems.
  • Manage MSL capabilities and performance through coaching, training, and development to ensure effective execution and achievement of strategic goals.
  • Support generation and communication of scientific and medical insights to internal stakeholders; develop and execute strategic and tactical Medical Engagement Plans; and manage MSL resources and budgets.
  • Partner with the Medical Director, medical advisors, and internal partners on regional stakeholder relationships, medical engagement planning, and MSL budgets.
  • Clarify and align MSL roles and responsibilities across internal and external stakeholders.
  • Analyze qualitative and quantitative information to determine the staff, tasks, and resources needed to achieve objectives.
  • Support MSL field-force resource planning for product pre-launch and lifecycle management.
  • Attend cross-functional and transversal meetings to collaborate with stakeholders affecting MSL strategy.
  • Identify and share MSL best practices across geographies.
  • Ensure territory MSL job descriptions align with country launch plans, medical or policy plans, and global guidance on MSL roles and responsibilities.
  • Ensure MSL annual planning, objectives, and KPIs are used, and support MSL managers in monitoring them.
  • Develop recruiting plans, build business cases, and secure approval for headcount changes.
  • Support MSL effectiveness measures and gap analyses, and align training and education curricula; identify synergies in company training resources and programs.
  • Align field medical tools and resources with medical strategy, and lead efficiency initiatives through implementation of optimized systems and tools.
  • Ensure field insights and feedback are captured and shared with Medical Affairs and relevant business partners.
  • Manage vendor relationships to meet business objectives, timelines, and budgets.
  • Ensure the MSL organization meets global, regional, local, and corporate training requirements and complies with applicable policies and regulations.
  • Collaborate with Head Office stakeholders to develop country- and territory-level Medical Engagement Plans.
  • Assess medical launch plans and regional medical strategies.
  • Support MSLs in identifying, mapping, and reviewing KOLs quarterly and developing customized engagement plans.
  • Monitor and support MSL execution of plans through regular coaching sessions.
  • Manage reporting on MSL performance against KPIs and support effective execution of strategic and tactical goals.
  • Support identification and prioritization of territory stakeholders and development of customized engagement plans.
  • Monitor MSL/KOL relationships through coaching sessions and field visits, ensuring high-quality, scientifically aligned exchanges.
  • Review, monitor, and analyze KOL insights about strategy, products, company image, and competition to assess needs, priorities, expectations, and satisfaction; engage selected external stakeholders as appropriate.
  • Support, attend, and follow up on scientific congresses, symposia, and other events as appropriate.
  • Collaborate with internal stakeholders to provide scientific input on materials and coordinate training support.
  • Provide or organize scientific and technical support for internal stakeholders developing medical strategy.
  • Aggregate and communicate KOL insights on scientific, medical, and clinical experience to stakeholders.
  • Facilitate exchange of medical leadership and best practices through communications, meetings, and events among MSLs and other functions locally and across geographies and GBUs.
  • Oversee MSL training, coaching, performance evaluations, recognition, disciplinary actions when needed, and career planning.
  • Set, track, and monitor KPIs and develop and execute corrective actions as needed.
  • Guide team reporting, planning, and monthly, quarterly, and annual KOL reviews in accordance with Medical Affairs strategy.
  • Regularly review and analyze field data and KOL feedback concerning company strategy, products, image, and competition.
  • For drivers under the manager’s supervision, support the Road Safety Program and ensure compliance.
Desired Qualifications
  • French is a definite asset.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...